Research and Markets (http://www.researchandmarkets.com/research/htvhsl/kit_receptor) has announced the addition of the "Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
The Kit receptor signaling pathway includes activation of PI 3-kinase, Src family kinases and PLC gamma. Activating mutations in the Kit receptor are associated with several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas.
There are today 193 companies plus partners developing 264 Kit receptor pathway targeting drugs in 1260 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 169 drugs.
Kit Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 166 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 163 out of the 165 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 37 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 35
- Registered - 1
- Pre-registration - 6
- Phase III - 32
- Phase II - 108
- Phase I - 125
- Preclinical - 131
- No Data - 9
- Suspended - 2
- Ceased - 169
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/htvhsl/kit_receptor
